Sosei Group Corporation (JP:4565)
:4565
Want to see JP:4565 full AI Analyst Report?
4565 Stock Chart & Stats
¥862.00
-¥10.00(-0.99%)
At close: 4:00 PM EST
¥862.00
-¥10.00(-0.99%)
Day’s Range― - ―
52-Week Range¥723.00 - ¥1,247.00
Previous CloseN/A
Volume458.60K
Average Volume (3M)945.56K
Market Cap
¥89.60B
Enterprise Value¥142.11B
Total Cash (Recent Filing)¥11.60B
Total Debt (Recent Filing)¥55.83B
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 07, 2026EPS Estimate
-3.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-110.53
Shares Outstanding92,462,690
10 Day Avg. Volume1,166,890
30 Day Avg. Volume945,556
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.22
Price to Sales (P/S)2.52
P/FCF Ratio-23.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)38.81
Revenue Forecast (FY)¥39.39B
Bulls Say, Bears Say
Bulls Say
Revenue Growth & MarginsTTM revenue growth of ~15.6% paired with ~72% gross margins indicates the core discovery and service economics are strong. High gross margins support reinvestment in R&D and make top-line gains more durable as collaborations scale and incremental revenue carries healthy contribution margins.
Capital Cushion (Equity)A stockholders' equity base of ~63.7B versus ~133.3B total assets provides a meaningful capital cushion. For an R&D-heavy biotech this reduces immediate liquidity pressure, lengthens runway for clinical programs, and lowers near-term refinancing urgency while management pursues milestones or licensing outcomes.
Partnership-driven Business ModelSosei’s model—GPCR structure-based drug design combined with collaborations—creates diversified, partner-funded development pathways. Upfronts, service fees, milestones and potential royalties distribute clinical and commercialization risk, enabling sustained program throughput without bearing full development costs.
Bears Say
Persistent UnprofitabilityDespite revenue growth, Sosei reports negative EBIT and a TTM net margin near -42%, reflecting elevated operating and development costs. Persistent losses weaken capital efficiency, limit internal funding capacity, and heighten dependence on external financing until partner milestones or product revenues change the profitability profile.
Negative Cash GenerationTTM operating cash flow and free cash flow are substantially negative, showing ongoing cash burn. This structural cash shortfall increases reliance on partner payments, milestone receipts or capital raises, which can dilute shareholders or be constrained in tighter markets and creates a persistent financing risk.
Elevated Leverage For A BiotechA debt-to-equity ratio near 0.94, with historical levels above 1.0, constitutes moderate-to-high leverage for a loss-making biotech. Debt service needs reduce strategic flexibility for R&D and deal-making, and increase vulnerability if cash flows remain negative or if access to capital markets tightens.
Sosei Group News
4565 FAQ
What was Sosei Group Corporation’s price range in the past 12 months?
Sosei Group Corporation lowest stock price was ¥723.00 and its highest was ¥1247.00 in the past 12 months.
What is Sosei Group Corporation’s market cap?
Sosei Group Corporation’s market cap is ¥89.60B.
When is Sosei Group Corporation’s upcoming earnings report date?
Sosei Group Corporation’s upcoming earnings report date is Aug 07, 2026 which is in 58 days.
How were Sosei Group Corporation’s earnings last quarter?
Sosei Group Corporation released its earnings results on May 01, 2026. The company reported ¥19.82 earnings per share for the quarter, beating the consensus estimate of N/A by ¥19.82.
Is Sosei Group Corporation overvalued?
According to Wall Street analysts Sosei Group Corporation’s price is currently Overvalued.
Does Sosei Group Corporation pay dividends?
Sosei Group Corporation pays a Notavailable dividend of ¥2.5 which represents an annual dividend yield of N/A. See more information on Sosei Group Corporation dividends here
What is Sosei Group Corporation’s EPS estimate?
Sosei Group Corporation’s EPS estimate is -3.53.
How many shares outstanding does Sosei Group Corporation have?
Sosei Group Corporation has 92,462,690 shares outstanding.
What happened to Sosei Group Corporation’s price movement after its last earnings report?
Sosei Group Corporation reported an EPS of ¥19.82 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.957%.
Which hedge fund is a major shareholder of Sosei Group Corporation?
Currently, no hedge funds are holding shares in JP:4565
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sosei Group Corporation
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
4565 Company Deck
4565 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong commercial execution in Japan/APAC and meaningful pipeline progress (Phase II–ready assets and partner-led late-stage programs) are clear positives, supported by rising product sales and a profitable commercial unit. However, FY2025 was marked by material operating losses, a notable decline in milestone revenue, higher R&D spend, and one-off charges. Management has announced restructuring, cost-reduction targets (>10%), and a plan to refocus the U.K. discovery portfolio, with expectations that benefits will appear in H2 FY2026. Given the balance between encouraging commercial/pipeline momentum and significant near-term financial and execution risks, the overall tone is cautious and transitional: opportunities exist but require successful execution of BD, cost actions, and regulatory steps to translate into the company’s stated FY2026 profitability goals.View all JP:4565 earnings summariesTechnical Analysis
Peptidream
―
SanBio Co
―
Oncolys BioPharma, Inc.
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
Options Prices
Currently, No data available
---